Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul><li>✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million shares at $15 to $17, targeting a valuation around $1.1 billion.</li><li>The company operates in precision proteomics, developing ultra-sensitive platforms capable of detecting low-abundance proteins for applications across early disease detection, drug development, and diagnostics.</li><li>The deal is being marketed to a concentrated base of healthcare-focused institutional investors during an active but selective biotech IPO window.</li></ul>

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million shares at $15 to $17, targeting a valuation around $1.1 billion.The company operates in precision proteomics, developing ultra-sensitive platforms capable of detecting low-abundance proteins for applications across early disease detection, drug development, and diagnostics.The deal is being marketed to a concentrated base of healthcare-focused institutional investors during an active but selective biotech IPO window.

<ul><li>Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .</li><li>The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. </li><li>Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.</li></ul>

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.</li>
<li>Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.</li>
<li>Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.</li>
</ul>


IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.
Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.
Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.


Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

<ul>
<li>Commercial-Stage proteomics company leveraging its proprietary NULISA platform to enable ultra-sensitive, high-plex protein detection for early disease detection and advanced research applications.</li>
<li>Demonstrates strong growth with revenue increasing from $25.1M to $74.2M (FY24–FY25), rapid customer adoption, and expanding instrument and assay utilization globally.</li>
<li>Backed by leading investors including Sands Capital, Illumina Ventures, and T. Rowe Price; filed for IPO March 27, positioning to capitalize on ~$50B+ growing proteomics and diagnostics markets.</li>
</ul>


Commercial-Stage proteomics company leveraging its proprietary NULISA platform to enable ultra-sensitive, high-plex protein detection for early disease detection and advanced research applications.
Demonstrates strong growth with revenue increasing from $25.1M to $74.2M (FY24–FY25), rapid customer adoption, and expanding instrument and assay utilization globally.
Backed by leading investors including Sands Capital, Illumina Ventures, and T. Rowe Price; filed for IPO March 27, positioning to capitalize on ~$50B+ growing proteomics and diagnostics markets.


Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

Attovia Therapeutics / Equity Capital Markets

<ul>
<li>Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.</li>
<li>Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.</li>
<li>Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.</li>
</ul>


Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.
Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.
Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.


Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alamar Biosciences (ALMR US)

IPO Rating: Alamar Bioscienes, Inc.

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality & Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million...

IPO Prophet

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares...

IPO Prophet

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

IPO Boutique

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

IPO Rating: Alamar Bioscienes, Inc.

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality & Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million...

IPO Prophet

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares...

IPO Prophet

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

​Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

​Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

IPO Boutique

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

​Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

Proteomics company with NULISA platform sees revenue growth, customer adoption, and IPO filing to capitalize on expanding markets.

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...